American Society of Hematology

ASH Meeting on Hematologic Malignancies

Hear top experts in hematologic malignancies discuss the latest developments in clinical care.

Learn more

Annual Meeting Registration

Register today for the 56th ASH Annual Meeting and Exposition.

Learn more

ASH Foundation 3K - 5K Run/Walk

December 7, 2014 - run or walk in the ASH Foundation 3K - 5K Run/Walk and help move hematology forward.

Learn more

Protect Medical Research

Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • Patients with Adverse Heparin Reaction May Be Ready for Urgent Heart Surgery Sooner with Combination of Blood Screenings, Plasma Exchange

    New evidence suggests that therapeutic plasma exchange and appropriate blood testing could help patients who are in urgent need of heart surgery, but have a history of an adverse reaction to the blood thinner heparin, according to a study published online today in Blood, the Journal of the American Society of Hematology.

  • American Society of Hematology Awards New Bridge Grants to Help Alleviate Pain of Federal Funding Cuts

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the names of seven recipients of its Bridge Grant awards. These one-year, $150,000 awards provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the National Institutes of Health (NIH) amid severe funding reductions. The ASH Bridge Grant award recipients announced today join 44 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in July 2012.

  • ASH Pairs Hematologists from Developing and Developed Nations for Global Training Program

    The American Society of Hematology (ASH) today announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity to receive training on a specific area of hematology from an ASH member located anywhere in the world for up to 12 weeks. The goal of this program is to build hematology capacity in developing countries and ultimately improve the care of patients with blood diseases worldwide.

  • ASH Statement on Inaugural World Thrombosis Day

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today joins the International Society on Thrombosis and Haemostasis (ISTH) and nearly 200 organizations worldwide to commemorate October 13, 2014, as the inaugural World Thrombosis Day, a day dedicated to raising awareness of potentially dangerous blood clots.

View all press releases
  • Institute of Medicine’s National Cancer Policy Forum Holds a Workshop on Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer

    ASH staff recently attended an IOM National Cancer Policy Forum workshop on policy issues in the development and adoption of molecularly targeted therapies for cancer.  The purpose of this workshop was to examine the recent trends in the development and implementation of molecularly targeted cancer therapies, address current challenges in the field, and to put forth potential strategies and policy action items that could improve current processes.


  • 2014 ASH Advocacy Efforts Related to Sickle Cell Disease

    ASH remains committed to working with various groups in the sickle cell stakeholder community, Congress, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and other federal agencies to increase research, treatment options, and access to care for patients with sickle cell disease and sickle cell trait.  Continue reading about the major initiatives undertaken by the Society in 2014.

  • 2014 ASH Advocacy Efforts to Ensure Access to Safe and Effective Hematologic Drugs

    Over the past several years, shortages of drugs and biologics used to treat patients with hematologic diseases, including leukemia and lymphoma, have become critical and life-threatening.  ASH has taken a number of steps to resolve these drug and biologic shortages, including working with manufacturers, the Food & Drug Administration (FDA) and Congress.  ASH continues to be actively involved in this issue.  Continue reading for a summary of recent ASH advocacy efforts to address drug and biologic shortages.

  • 2014 NIH Funding Advocacy Highlights

    During 2014, ASH has continued to be one of the most visible advocates for federal support of biomedical research and funding for the National Institutes of Health (NIH).  Continue reading for a summary of ASH's 2014 advocacy efforts.

View all policy news
View all Hematologist articles